Literature DB >> 15132987

Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death.

Gang Chen1, Kimberly A Bower, Cuiling Ma, Shengyun Fang, Carol J Thiele, Jia Luo.   

Abstract

The causes of sporadic Parkinson's disease (PD) are poorly understood. 6-Hydroxydopamine (6-OHDA), a PD mimetic, is widely used to model this neurodegenerative disorder in vitro and in vivo; however, the underlying mechanisms remain incompletely elucidated. We demonstrate here that 6-OHDA evoked endoplasmic reticulum (ER) stress, which was characterized by an up-regulation in the expression of GRP78 and GADD153 (Chop), cleavage of procaspase-12, and phosphorylation of eukaryotic initiation factor-2 alpha in a human dopaminergic neuronal cell line (SH-SY5Y) and cultured rat cerebellar granule neurons (CGNs). Glycogen synthase kinase-3 beta (GSK3beta) responds to ER stress, and its activity is regulated by phosphorylation. 6-OHDA significantly inhibited phosphorylation of GSK3beta at Ser9, whereas it induced hyperphosphorylation of Tyr216 with little effect on GSK3beta expression in SH-SY5Y cells and PC12 cells (a rat dopamine cell line), as well as CGNs. Furthermore, 6-OHDA decreased the expression of cyclin D1, a substrate of GSK3beta, and dephosphorylated Akt, the upstream signaling component of GSK3beta. Protein phosphatase 2A (PP2A), an ER stress-responsive phosphatase, was involved in 6-OHDA-induced GSK3beta dephosphorylation (Ser9). Blocking GSK3beta activity by selective inhibitors (lithium, TDZD-8, and L803-mts) prevented 6-OHDA-induced cleavage of caspase-3 and poly(ADP-ribose) polymerase (PARP), DNA fragmentations and cell death. With a tetracycline (Tet)-controlled TrkB inducible system, we demonstrated that activation of TrkB in SH-SY5Y cells alleviated 6-OHDA-induced GSK3beta dephosphorylation (Ser9) and ameliorated 6-OHDA neurotoxicity. TrkB activation also protected CGNs against 6-OHDA-induced damage. Although antioxidants also offered neuroprotection, they had little effect on 6-OHDA-induced GSK3beta activation. These results suggest that GSK3beta is a critical intermediate in pro-apoptotic signaling cascades that are associated with neurodegenerative diseases, thus providing a potential target site amenable to pharmacological intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15132987     DOI: 10.1096/fj.04-1551fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  124 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.

Authors:  Ravi S Akundi; Lianteng Zhi; Hansruedi Büeler
Journal:  Neurobiol Dis       Date:  2011-09-16       Impact factor: 5.996

3.  An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease.

Authors:  Chee Yeun Chung; James B Koprich; Shogo Endo; Ole Isacson
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

Review 4.  The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.

Authors:  Eléonore Beurel; Richard S Jope
Journal:  Prog Neurobiol       Date:  2006-08-28       Impact factor: 11.685

5.  Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency.

Authors:  Taj D King; Buffie Clodfelder-Miller; Keri A Barksdale; Gautam N Bijur
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

6.  Lithium prevents acrolein-induced neurotoxicity in HT22 mouse hippocampal cells.

Authors:  Yingjuan Huang; Jian Qin; Meihui Chen; Xiaojuan Chao; Ziwei Chen; Charles Ramassamy; Rongbiao Pi; Minghua Jin
Journal:  Neurochem Res       Date:  2014-02-13       Impact factor: 3.996

7.  Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death.

Authors:  Irene Cappuccio; Agata Calderone; Carla L Busceti; Francesca Biagioni; Fabrizio Pontarelli; Valeria Bruno; Marianna Storto; Georg T Terstappen; Giovanni Gaviraghi; Francesco Fornai; Giuseppe Battaglia; Daniela Melchiorri; R Suzanne Zukin; Suzanne Zukin; Ferdinando Nicoletti; Andrea Caricasole
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

8.  Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.

Authors:  J A Morales-García; C Susín; S Alonso-Gil; D I Pérez; V Palomo; C Pérez; S Conde; A Santos; C Gil; A Martínez; A Pérez-Castillo
Journal:  ACS Chem Neurosci       Date:  2012-12-05       Impact factor: 4.418

9.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

10.  Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine.

Authors:  April A Dukes; Victor S Van Laar; Michael Cascio; Teresa G Hastings
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.